Trials / Completed
CompletedNCT01973491
ATX-MS-1467 in Multiple Sclerosis
An Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 (MSC2358825A) and Its Effect on Immune Tolerance in Subjects With Relapsing Multiple Sclerosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Merck KGaA, Darmstadt, Germany · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, open-label, single arm, baseline-controlled Phase 2a trial to evaluate the clinical and biological effects of ATX-MS-1467 in subjects with relapsing multiple sclerosis (MS) and to assess the maintenance of any such effects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ATX-MS-1467 | Subjects will receive ATX-MS-1467 50 microgram (mcg), 200 mcg and 800 mcg on Day 1, Day 15 and Day 29 respectively during the titration period followed by biweekly dose of ATX-MS-1467 800 mcg for 16 weeks during the treatment period. |
Timeline
- Start date
- 2014-02-28
- Primary completion
- 2016-04-30
- Completion
- 2016-04-30
- First posted
- 2013-10-31
- Last updated
- 2017-07-02
- Results posted
- 2017-04-13
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01973491. Inclusion in this directory is not an endorsement.